Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Topoisomerase I interactive agents.

Mark N Kirstein1, P Kellie Turner, Clinton F Stewart

  • 1Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, 332 N. Lauderdale, Memphis, TN 38105, USA.

Cancer Chemotherapy and Biological Response Modifiers
|April 22, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Model-Informed Early Prediction of Methotrexate-Induced Acute Kidney Injury in Pediatric Patients with Osteosarcoma Using Real-World Data: A Multi-center Pharmacokinetic Study.

Clinical pharmacokinetics·2026
Same author

Evaluation of Growth Differentiation Factor 15 as an Early Biomarker of Anthracycline-Induced Cardiotoxicity Using an Integrated PK/PD Model.

Clinical and translational science·2026
Same author

Targeting the p53 pathway to treat atypical teratoid rhabdoid tumors.

Neuro-oncology pediatrics·2026
Same author

Longitudinal Tumor Size and Survival Modeling for Exposure-Response Analysis of Drugs with Frequent Dose Reductions: Dose Justification of Abemaciclib in Patients with Metastatic Breast Cancer.

Clinical pharmacology and therapeutics·2026
Same author

Preclinical and clinical evaluation of LY3451838, a PACAP-neutralizing monoclonal antibody, in randomized, double-blind, placebo-controlled phase 1 and phase 2 studies involving healthy adults and adults with treatment-resistant migraine.

Cephalalgia : an international journal of headache·2025
Same author

Quantitative determination of Selinexor concentrations in plasma samples from children with non-rhabdomyosarcoma soft-tissue sarcomas: Troubleshooting plasma instability issues.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences·2025
Same journal

Native and genetically engineered anti-disialoganglioside monoclonal antibody treatment of melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Human tumor associated antigen mimicry by xenoantigens, anti-idiotypic antibodies and peptide mimics: implications for immunotherapy of malignant diseases.

Cancer chemotherapy and biological response modifiers·2005
Same journal

DNA vaccines for melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Immunizing against partially defined antigen mixtures, gangliosides, or peptides to induce antibody, T cell, and clinical responses.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Chemotherapy, cytokines, and biochemotherapy for melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Current status of interferon-alpha in the treatment of melanoma.

Cancer chemotherapy and biological response modifiers·2005
See all related articles

Understanding topoisomerase I interactions is key for developing better cancer drugs. Further research on drug mechanisms and optimal dosing schedules will improve patient outcomes and guide future therapeutic strategies.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Oncology

Background:

  • Topoisomerase I (TOP1) interactive agents, initially camptothecin derivatives, are crucial in cancer therapy.
  • Rational drug design requires understanding the precise mechanism of TOP1 interaction and its effect on cell death.

Purpose of the Study:

  • To explore the significance of TOP1 crystal structure elucidation for developing novel TOP1 interactive agents.
  • To emphasize the need for preclinical studies to determine mechanisms of action and optimize dosing strategies for existing and future TOP1 inhibitors.
  • To guide future clinical trials in designing effective combination regimens and optimizing administration schedules for improved therapeutic indices.

Main Methods:

  • Elucidation of topoisomerase I crystal structure.

Related Experiment Videos

  • Preclinical studies investigating mechanisms of cell death induced by TOP1 inhibitors.
  • Analysis of pharmacokinetic and pharmacodynamic data to determine optimal dosing schedules.
  • Investigation of mechanisms underlying dose-limiting toxicities of current TOP1 inhibitors.

    • Main Results:

    • Knowledge of TOP1 structure facilitates rational design of improved interactive agents.
    • Preclinical data suggest protracted dosing for S-phase-specific agents like irinotecan and topotecan.
    • Understanding toxicity mechanisms, such as irinotecan glucuronidation, can inform maximal dosing strategies.

    Conclusions:

    • Optimizing the use of current topoisomerase I inhibitors through rigorous preclinical and clinical studies is paramount.
    • Future drug development should leverage structural and mechanistic insights for rational design and improved therapeutic outcomes.
    • Continued research into TOP1 inhibitor mechanisms and toxicities is essential for maximizing their clinical benefit.